Contact

All Stories

  1. Pharmacological chemoprevention of hepatocellular carcinoma: hype, hope, or reality?

    Article • Hepatoma Research, August 2026, OAE Publishing

    Professor Amedeo LONARDO

  2. Inter-Organ Crosstalk in MASLD: A Narrative Review

    Article • August 2026, MDPI AG

    Professor Amedeo LONARDO

  3. Metabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine

    Article • Metabolites, July 2026, MDPI AG

    Professor Amedeo LONARDO

  4. The Liver Left Behind: GLP-1 Receptor Agonists and the Prospect of Metabolic Adjuvant Therapy After HCC Resection

    Article • Metabolites, July 2026, MDPI AG

    Professor Amedeo LONARDO

  5. Metabolic Rewiring in MASLD: From Disease Mechanisms to Precision Medicine

    Article • July 2026, MDPI AG

    Professor Amedeo LONARDO

  6. Sex differences in MASLD-related atherosclerosis: plaque phenotype, vascular dysfunction, and cardiovascular outcomes

    Article • Biology of Sex Differences, July 2026, Springer Science + Business Media

    Professor Amedeo LONARDO

  7. How Physiology and Pharmacology Shape Liver Regeneration: From Molecules and Cells to Trials

    Article • International Journal of Molecular Sciences, July 2026, MDPI AG

    Professor Amedeo LONARDO

  8. Current Insights into Liver Fibrosis: Epidemiological Patterns, Etiopathogenesis, Clinical Correlates, and Research Agenda

    Article • June 2026, MDPI AG

    Professor Amedeo LONARDO

  9. Physiopharmacology of Liver Regeneration from Molecules to Trials

    Article • May 2026, MDPI AG

    Professor Amedeo LONARDO

  10. Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era

    Article • Oncology and Therapy, May 2026, Springer Science + Business Media

    Professor Amedeo LONARDO

  11. X-chromosome gene dosage shapes MASLD beyond sex hormones

    Article • Trends in Endocrinology and Metabolism, May 2026, Elsevier

    Professor Amedeo LONARDO

  12. Lipids at the helm: a metabolic playbook for liver regeneration

    Article • Metabolism and Target Organ Damage, March 2026, OAE Publishing

    Professor Amedeo LONARDO

  13. Burden of Liver Disease Among Individuals With Turner Syndrome and Klinefelter Syndrome: A Comprehensive Perspective

    Article • Chronic Diseases and Translational Medicine, February 2026, Wiley

    Professor Amedeo LONARDO

  14. Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment

    Article • Exploration of Digestive Diseases, February 2026, Open Exploration Publishing

    Professor Amedeo LONARDO

  15. Treating obesity with GLP-1 RAs: does sex matter? A commentary on the meta-analysis by Yang et al. (J Diabetes 2025;17(3):e70063)

    Article • Exploration of Endocrine and Metabolic Diseases, February 2026, Open Exploration Publishing

    Professor Amedeo LONARDO

  16. Biological determinants and outcomes of sex discrepancies in MASLD

    Article • Metabolism and Target Organ Damage, January 2026, OAE Publishing

    Professor Amedeo LONARDO

  17. Liver Fibrosis and the Risks of Impaired Cognition and Dementia: Mechanisms, Evidence, and Clinical Implications

    Article • Medical Sciences, January 2026, MDPI AG

    Professor Amedeo LONARDO

  18. Mitochondrial medicine in obesity: a scoping review

    Article • Open Medicine, January 2026, De Gruyter

    Professor Amedeo LONARDO

  19. Obesity, Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatocellular Carcinoma: How Molecular Changes Impact Cellular Functions

    Article • BIOCELL, January 2026, Tsinghua University Press

    Professor Amedeo LONARDO

  20. Drug treatment of MASH from none to (too) many options?

    Article • Exploration of Medicine, December 2025, Open Exploration Publishing

    Professor Amedeo LONARDO

  21. Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer

    Article • Biomolecules, December 2025, MDPI AG

    Professor Amedeo LONARDO

  22. Liver Fibrosis and the Risks of Impaired Cognition and Dementia: Mechanisms, Evidence, and Clinical Implications

    Article • December 2025, MDPI AG

    Professor Amedeo LONARDO

  23. Unraveling One-Carbon Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease: Semaglutide Turns Metabolic Stress Into Metabolic Resilience

    Article • Cellular and Molecular Medicine Research, December 2025, Elmer Press, Inc.

    Professor Amedeo LONARDO

  24. Sex differences in alcohol-related liver disease, viral hepatitis, metabolic dysfunction-associated steatotic liver disease, and hepatocellular carcinoma

    Article • Exploration of Digestive Diseases, November 2025, Open Exploration Publishing

    Professor Amedeo LONARDO

  25. Stopping SOAT1 sparks an immune attack on liver cancer: a metabolic-immune axis in hepatocellular carcinoma

    Article • ONCOLOGIE, November 2025, De Gruyter

    Professor Amedeo LONARDO

  26. Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders

    Article • Medical Sciences, November 2025, MDPI AG

    Professor Amedeo LONARDO

  27. Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure, and Cancer

    Article • November 2025, MDPI AG

    Professor Amedeo LONARDO

  28. Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders

    Article • October 2025, MDPI AG

    Professor Amedeo LONARDO

  29. Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease

    Article • International Journal of Molecular Sciences, October 2025, MDPI AG

    Professor Amedeo LONARDO

  30. Tirzepatide in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: a novel star on the horizon?

    Article • Exploration of Drug Science, September 2025, Open Exploration Publishing

    Professor Amedeo LONARDO

  31. PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD

    Article • Exploration of Digestive Diseases, September 2025, Open Exploration Publishing

    Professor Amedeo LONARDO

  32. MASLD vs. MAFLD. A narrative review

    Article • Exploration of Digestive Diseases, August 2025, Open Exploration Publishing

    Professor Amedeo LONARDO

  33. Food insecurity is an emerging risk factor for liver disease: a scoping review

    Article • Expert Review of Gastroenterology & Hepatology, August 2025, Taylor & Francis

    Professor Amedeo LONARDO

  34. The Ovary–Liver Axis: Molecular Science and Epidemiology

    Article • International Journal of Molecular Sciences, July 2025, MDPI AG

    Professor Amedeo LONARDO

  35. Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer

    Article • Trends in Endocrinology and Metabolism, July 2025, Elsevier

    Professor Amedeo LONARDO

  36. Metabolic dysfunction‐associated steatotic liver disease and sex‐specific risk of fatal and non‐fatal cardiovascular events: A meta‐analysis

    Article • Diabetes Obesity and Metabolism, June 2025, Wiley

    Professor Amedeo LONARDO

  37. Liver and obesity: a narrative review

    Article • Exploration of Medicine, June 2025, Open Exploration Publishing

    Professor Amedeo LONARDO

  38. Targeting duodenum to reverse MASLD

    Article • Exploration of Digestive Diseases, June 2025, Open Exploration Publishing

    Professor Amedeo LONARDO

  39. Not all fat is alike in MASLD

    Article • Journal of Hepatology, May 2025, Elsevier

    Professor Amedeo LONARDO

  40. Abdominal Aortic Aneurysm and Liver Fibrosis: Clinical Evidence and Molecular Pathomechanisms

    Article • International Journal of Molecular Sciences, April 2025, MDPI AG

    Professor Amedeo LONARDO

  41. Duodenal mucosa resurfacing: the endoscopic silver bullet against metabolic disorders?

    Article • Metabolism and Target Organ Damage, March 2025, OAE Publishing

    Professor Amedeo LONARDO

  42. Abdominal Aortic Aneurysm and Liver Fibrosis. Clinical Evidence and Molecular Pathomechanics

    Article • March 2025, MDPI AG

    Professor Amedeo LONARDO

  43. Cardiovascular Mortality in MASLD: A Matter of Fat. Caution in Interpreting Liver Fat Quantification in Populations With High Fibrosis Variability

    Article • Liver International Communications, February 2025, Wiley

    Professor Amedeo LONARDO

  44. PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology

    Article • Journal of Translational Genetics and Genomics, December 2024, OAE Publishing

    Professor Amedeo LONARDO

  45. Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021

    Article • Clinical Nutrition, December 2024, Elsevier

    Professor Amedeo LONARDO

  46. Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease

    Article • Metabolism and Target Organ Damage, November 2024, OAE Publishing

    Professor Amedeo LONARDO

  47. MASLD: predictive value for liver-related events and extra-hepatic complications

    Article • Expert Review of Gastroenterology & Hepatology, November 2024, Taylor & Francis

    Professor Amedeo LONARDO

  48. Intravenous lactated Ringer’s solution alone and in combination with NSAIDs in prevention of post-ERCP acute pancreatitis: an updated systematic review

    Article • Exploration of Medicine, October 2024, Open Exploration Publishing

    Professor Amedeo LONARDO

  49. Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both

    Article • Journal of Hepatology, October 2024, Elsevier

    Professor Amedeo LONARDO

  50. Copper and liver fibrosis in MASLD: the two-edged sword of copper deficiency and toxicity

    Article • Metabolism and Target Organ Damage, September 2024, OAE Publishing

    Professor Amedeo LONARDO

  51. Editorial - Reflecting on three years of M&TOD - Where we are and where we are going

    Article • Metabolism and Target Organ Damage, August 2024, OAE Publishing

    Professor Amedeo LONARDO

  52. From Hypothalamic Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease: Physiology Meets the Clinics via Metabolomics

    Article • Metabolites, July 2024, MDPI AG

    Professor Amedeo LONARDO

  53. Liver fibrosis: More than meets the eye

    Article • Annals of Hepatology, July 2024, Elsevier

    Professor Amedeo LONARDO

  54. Does an Aspirin a Day Take the MASLD Away?

    Article • Advances in Therapy, May 2024, Springer Science + Business Media

    Professor Amedeo LONARDO

  55. Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature

    Article • Journal of Hepatology, May 2024, Elsevier

    Clinical Chair Professor Henning Gronbaek, Professor Amedeo LONARDO

  56. PRO‐C3, liver fibrosis and CKD: The plot thickens

    Article • Liver International, April 2024, Wiley

    Professor Amedeo LONARDO

  57. Resmetirom: Finally, the Light at the End of the NASH Tunnel?

    Article • Livers, February 2024, MDPI AG

    Professor Amedeo LONARDO

  58. Endpoints in NASH Clinical Trials: Are We Blind in One Eye?

    Article • Metabolites, January 2024, MDPI AG

    Professor Amedeo LONARDO

  59. MASLD co-aggregates with HCC in families-names change, fa(c)ts remain

    Article • Hepatoma Research, December 2023, OAE Publishing

    Professor Amedeo LONARDO

  60. Reactivation of latent hepatitis B infection during immunosuppressive therapy with guselkumab for plaque psoriasis: a case report

    Article • December 2023, Open Exploration Publishing

    Professor Amedeo LONARDO

  61. Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases

    Article • Nature Reviews Gastroenterology & Hepatology, December 2023, Springer Science + Business Media

    Professor Amedeo LONARDO

  62. The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers

    Article • Expert Review of Clinical Pharmacology, September 2023, Taylor & Francis

    Professor Amedeo LONARDO

  63. Principles of risk stratification in nonalcoholic fatty liver disease. A narrative review emphasizing non-invasive strategies

    Article • August 2023, Open Exploration Publishing

    Professor Amedeo LONARDO

  64. Iron depletion in “metabolic fatty liver syndromes”: a strong biological rationale with disappointing liver outcomes

    Article • August 2023, Open Exploration Publishing

    Professor Amedeo LONARDO

  65. Shutting those revolving doors

    Article • Annals of Hepatology, July 2023, Elsevier

    Professor Amedeo LONARDO

  66. Extra-hepatic cancers in metabolic fatty liver syndromes

    Article • February 2023, Open Exploration Publishing

    Professor Amedeo LONARDO

  67. Rewriting the natural history of MAFLD on the basis of cardiovascular risk assessment

    Article • Nutrition Metabolism and Cardiovascular Diseases, February 2023, Elsevier

    Professor Amedeo LONARDO

  68. Digging the metabolic roots of NASH up

    Article • Life Metabolism, December 2022, Oxford University Press (OUP)

    Professor Amedeo LONARDO

  69. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications

    Article • International Journal of Molecular Sciences, November 2022, MDPI AG

    Professor Amedeo LONARDO

  70. Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation

    Article • Nature Reviews Endocrinology, July 2022, Springer Science + Business Media

    Professor Amedeo LONARDO

  71. Precision medicine in nonalcoholic fatty liver disease

    Article • Journal of Gastroenterology and Hepatology, July 2022, Wiley

    Professor Amedeo LONARDO

  72. Metabolomic signature: one step forward in the process of obtaining NAFLD patients’ metabolic identity card

    Article • American Journal of Clinical Nutrition, March 2022, Elsevier

    Professor Amedeo LONARDO

  73. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine

    Article • Exploration of Medicine, October 2021, Open Exploration Publishing

    Professor Amedeo LONARDO

  74. Back to the future: From the history of NAFLD to MAFLD to heterogeneity of disease

    Article • Clinical and Translational Discovery, October 2021, Wiley

    Professor Amedeo LONARDO

  75. How Much Vitamin D is Too Much? A Case Report and Review of the Literature

    Article • Endocrine Metabolic & Immune Disorders - Drug Targets, September 2021, Bentham Science Publishers

    Professor Vincenzo - Rochira, Manuela Simoni, Professor Amedeo LONARDO

  76. Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues

    Article • Nutrition Metabolism and Cardiovascular Diseases, July 2021, Elsevier

    Professor Amedeo LONARDO

  77. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

    Article • Advances in Therapy, April 2021, Springer Science + Business Media

    Professor Amedeo LONARDO

  78. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?

    Article • Journal of Clinical Medicine, January 2021, MDPI AG

    Professor Amedeo LONARDO

  79. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

    Article • Metabolites, January 2021, MDPI AG

    Professor Amedeo LONARDO

  80. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease

    Article • Diagnostics, January 2021, MDPI AG

    Professor Amedeo LONARDO, Stefano Ballestri

  81. Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

    Article • January 2021, OAE Publishing

    Professor Amedeo LONARDO

  82. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis

    Article • Gut, December 2020, BMJ

    Professor Amedeo LONARDO

  83. Semi-Quantitative Ultrasonographic Evaluation of NAFLD

    Article • Current Pharmaceutical Design, September 2020, Bentham Science Publishers

    Claudio Tana, Professor Amedeo LONARDO, Stefano Ballestri

  84. History of Nonalcoholic Fatty Liver Disease

    Article • International Journal of Molecular Sciences, August 2020, MDPI AG

    Professor Amedeo LONARDO

  85. Perspectives of nonalcoholic fatty liver disease research: a personal point of view

    Article • May 2020, Open Exploration Publishing

    Professor Amedeo LONARDO

  86. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research

    Article • Journal of Clinical Medicine, April 2020, MDPI AG

    Professor Amedeo LONARDO

  87. NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management

    Article • International Journal of Molecular Sciences, June 2019, MDPI AG

    Professor Amedeo LONARDO

  88. A critical appraisal of the use of ultrasound in hepatic steatosis

    Article • Expert Review of Gastroenterology & Hepatology, May 2019, Taylor & Francis

    Professor Amedeo LONARDO, Dr Giampiero Francica, stefano ballestri, Stefano Ballestri

  89. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes

    Article • Atherosclerosis, May 2019, Elsevier

    Professor Amedeo LONARDO

  90. Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?

    Article • Digestive and Liver Disease, April 2019, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  91. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?

    Article • Acta Diabetologica, December 2018, Springer Science + Business Media

    Professor Amedeo LONARDO, Stefano Ballestri

  92. Telomere shortening: An innocent bystander at the crossroad of NASH with ageing and cardiometabolic risk?

    Article • Liver International, September 2018, Wiley

    Professor Amedeo LONARDO

  93. Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?

    Article • Diseases, February 2018, MDPI AG

    Professor Amedeo LONARDO

  94. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?

    Article • Journal of Hepatology, February 2018, Elsevier

    Professor Amedeo LONARDO

  95. NAFLD: Is There Anything New under the Sun?

    Article • International Journal of Molecular Sciences, September 2017, MDPI AG

    Professor Amedeo LONARDO

  96. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases

    Article • Metabolism, July 2017, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  97. Nonalcoholic fatty liver disease and COPD. Are they mutually associated ?

    Article • European Respiratory Journal, June 2017, European Respiratory Society (ERS)

    Professor Amedeo LONARDO

  98. Metabolic concerns in aging HIV-infected persons

    Article • AIDS, June 2017, Wolters Kluwer Health

    Professor Amedeo LONARDO

  99. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk

    Article • Advances in Therapy, May 2017, Springer Science + Business Media

    Professor Amedeo LONARDO, Stefano Ballestri

  100. AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions

    Article • Digestive and Liver Disease, May 2017, Elsevier

    Professor Amedeo LONARDO, Dr Amalia Gastaldelli

  101. NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk

    Article • Hepatology, April 2017, Wiley

    Professor Amedeo LONARDO, Stefano Ballestri

  102. “ Not all forms of NAFLD were created equal ”. Do metabolic syndrome-related NAFLD and PNPLA3 -related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?

    Article • Atherosclerosis, February 2017, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  103. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis

    Article • World Journal of Gastroenterology, January 2017, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Professor Amedeo LONARDO, Stefano Ballestri

  104. Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy

    Article • Digestive and Liver Disease, November 2016, Elsevier

    Professor Amedeo LONARDO

  105. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

    Article • Journal of Hepatology, September 2016, Elsevier

    Professor Amedeo LONARDO

  106. Non-alcoholic fatty liver disease and risk of cardiovascular disease

    Article • Metabolism, August 2016, Elsevier

    Professor Amedeo LONARDO

  107. Alcohol and Steatosis: The Japanese Paradox

    Article • EBioMedicine, June 2016, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  108. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes

    Article • Hepatology, May 2016, Wiley

    Professor Amedeo LONARDO

  109. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis

    Article • Journal of Gastroenterology and Hepatology, April 2016, Wiley

    Professor Amedeo LONARDO, Stefano Ballestri

  110. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.

    Article • Hepatology Research, March 2016, Wiley

    Professor Amedeo LONARDO, Stefano Ballestri

  111. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection—Liver: The “Musketeer” in the Spotlight

    Article • International Journal of Molecular Sciences, March 2016, MDPI AG

    Professor Amedeo LONARDO, Stefano Ballestri

  112. A “systems medicine” approach to the study of non-alcoholic fatty liver disease

    Article • Digestive and Liver Disease, March 2016, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  113. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans

    Article • Advances in Therapy, February 2016, Springer Science + Business Media

    Professor Amedeo LONARDO, Stefano Ballestri

  114. Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?

    Article • International Journal of Molecular Sciences, February 2016, MDPI AG

    Professor Amedeo LONARDO

  115. Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure

    Article • Medicine, February 2016, Wolters Kluwer Health

    Professor Amedeo LONARDO

  116. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease

    Article • Digestive Diseases and Sciences, January 2016, Springer Science + Business Media

    Professor Amedeo LONARDO, Stefano Ballestri

  117. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV

    Article • World Journal of Gastroenterology, January 2016, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Professor Amedeo LONARDO, Stefano Ballestri

  118. Gamma glutamyl transferase: A novel cardiovascular outfit for an old liver test

    Article • International Journal of Microbiology Research, January 2016, Medknow

    Professor Amedeo LONARDO

  119. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups

    Article • Digestive and Liver Disease, December 2015, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  120. Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma

    Article • Journal of Clinical Virology, August 2015, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  121. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?

    Article • Endocrine, May 2015, Springer Science + Business Media

    Professor Amedeo LONARDO

  122. Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?

    Article • Journal of Endocrinological Investigation, May 2015, Springer Science + Business Media

    Professor Amedeo LONARDO

  123. Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?

    Article • Liver International, May 2015, Wiley

    Professor Amedeo LONARDO, Stefano Ballestri

  124. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome

    Article • Digestive and Liver Disease, March 2015, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  125. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications

    Article • Expert Review of Gastroenterology & Hepatology, February 2015, Taylor & Francis

    Dr Giampiero Francica, Professor Amedeo LONARDO, stefano ballestri, Stefano Ballestri

  126. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease

    Article • Expert Review of Gastroenterology & Hepatology, October 2014, Taylor & Francis

    Professor Amedeo LONARDO, Stefano Ballestri

  127. Primary lymphoma of the spleen mimicking simple benign cysts: contrast-enhanced ultrasonography and other imaging findings

    Article • Journal of Medical Ultrasonics, October 2014, Springer Science + Business Media

    Professor Amedeo LONARDO, Stefano Ballestri

  128. Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity?

    Article • Digestive and Liver Disease, March 2014, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  129. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology

    Article • Atherosclerosis, January 2014, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  130. Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms

    Article • World Journal of Gastroenterology, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Professor Amedeo LONARDO

  131. Nonalcoholic fatty liver disease and aging: Epidemiology to management

    Article • World Journal of Gastroenterology, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Professor Amedeo LONARDO, Stefano Ballestri

  132. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen

    Article • World Journal of Gastroenterology, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Professor Amedeo LONARDO, Stefano Ballestri

  133. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease

    Article • World Journal of Gastroenterology, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Professor Amedeo LONARDO, Stefano Ballestri

  134. From NAFLD in clinical practice to answers from guidelines

    Article • Journal of Hepatology, October 2013, Elsevier

    Professor Amedeo LONARDO

  135. Use of procalcitonin for the differential diagnosis of fever in cancer patients: an observational study

    Article • Italian Journal of Medicine, September 2013, PAGEPress Publications

    Professor Amedeo LONARDO

  136. Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD)

    Article • Clinics and Research in Hepatology and Gastroenterology, September 2013, Elsevier

    Professor Amedeo LONARDO

  137. Relationship of Serum Fetuin-A Levels with Coronary Atherosclerotic Burden and NAFLD in Patients Undergoing Elective Coronary Angiography

    Article • Metabolic Syndrome and Related Disorders, August 2013, Mary Ann Liebert Inc

    Professor Amedeo LONARDO, Stefano Ballestri

  138. Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD

    Article • Current Pharmaceutical Design, July 2013, Bentham Science Publishers

    Professor Amedeo LONARDO

  139. HCV treatment in patients with metabolic syndrome

    Article • May 2013, Future Medicine

    Professor Amedeo LONARDO

  140. Liver and diabetes. A vicious circle

    Article • Hepatology Research, January 2013, Wiley

    Professor Amedeo LONARDO

  141. Potential for statins in the chemoprevention and management of hepatocellular carcinoma

    Article • Journal of Gastroenterology and Hepatology, October 2012, Wiley

    Professor Amedeo LONARDO

  142. Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis

    Article • Hepatology Research, August 2012, Wiley

    Professor Amedeo LONARDO, Stefano Ballestri

  143. If steatosis is the atherosclerosis of the liver, are statins the “aspirin” for steatosis?

    Article • Digestive and Liver Disease, June 2012, Elsevier

    Professor Amedeo LONARDO

  144. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD

    Article • Liver International, April 2012, Wiley

    Professor Amedeo LONARDO, Stefano Ballestri

  145. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis

    Article • Atherosclerosis, April 2012, Elsevier

    Professor Amedeo LONARDO

  146. Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease

    Article • Archives of Medical Research, November 2011, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  147. Metabolic alterations and chronic hepatitis C: treatment strategies

    Article • Expert Opinion on Pharmacotherapy, September 2011, Informa Healthcare

    Professor Amedeo LONARDO

  148. Treatment of Atherogenic Liver Based on the Pathogenesis of Nonalcoholic Fatty Liver Disease: A Novel Approach to Reduce Cardiovascular Risk?

    Article • Archives of Medical Research, July 2011, Elsevier

    Professor Amedeo LONARDO, Stefano Ballestri

  149. Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: What do they mean and do they agree?

    Article • Hepatology, May 2011, Wiley

    Professor Amedeo LONARDO, Stefano Ballestri

  150. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?

    Article • Internal and Emergency Medicine, May 2011, Springer Science + Business Media

    Professor Amedeo LONARDO, Stefano Ballestri

  151. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies?

    Article • Expert Review of Gastroenterology & Hepatology, April 2011, Taylor & Francis

    Professor Amedeo LONARDO

  152. Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: a case of ‘multiorganelle failure’? Proceedings of a virtual workshop on nonalcoholic steatohepatitis

    Article • Expert Review of Gastroenterology & Hepatology, April 2011, Taylor & Francis

    Professor Amedeo LONARDO

  153. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment

    Article • Expert Review of Endocrinology & Metabolism, May 2010, Taylor & Francis

    Professor Amedeo LONARDO

  154. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease

    Article • Digestive and Liver Disease, April 2010, Elsevier

    Professor Amedeo LONARDO

  155. Nonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase Inhibitors

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, February 2010, Wolters Kluwer Health

    Professor Amedeo LONARDO, Stefano Ballestri

  156. Genetic polymorphisms in non-alcoholic fatty liver disease: Interleukin-6−174G/C polymorphism is associated with non-alcoholic steatohepatitis

    Article • Digestive and Liver Disease, November 2009, Elsevier

    Professor Amedeo LONARDO

  157. NAFLD and Cardiovascular Risk: Direct Evidence for the Tale of Two Ages

    Article • The American Journal of Gastroenterology, July 2009, Springer Science + Business Media

    Professor Amedeo LONARDO

  158. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes

    Article • Journal of Gastroenterology and Hepatology, May 2009, Wiley

    Professor Amedeo LONARDO, Stefano Ballestri

  159. Endocrine and liver interaction: the role of endocrine pathways in NASH

    Article • Nature Reviews Gastroenterology & Hepatology, April 2009, Springer Science + Business Media

    Professor Amedeo LONARDO

  160. Hepatitis C and diabetes: the inevitable coincidence?

    Article • Expert Review of Anti-infective Therapy, April 2009, Taylor & Francis

    Professor Amedeo LONARDO

  161. Fatty Liver and Carotid Intimal Thickening: A Tale of Two Ages?

    Article • The American Journal of Gastroenterology, March 2009, Springer Science + Business Media

    Professor Amedeo LONARDO

  162. Hepatitis C Virus-Infected Patients Are ‘Spared’ from the Metabolic Syndrome but Not from Insulin Resistance. A Comparative Study of Nonalcoholic Fatty Liver Disease and Hepatitis C Virus-Related Steatosis

    Article • Canadian Journal of Gastroenterology, January 2009, Hindawi Publishing Corporation

    Professor Amedeo LONARDO

  163. The hepatitis C virus-associated dysmetabolic syndrome

    Article • Hepatology, September 2008, Wiley

    Professor Amedeo LONARDO

  164. Statins in liver disease: A molehill, an iceberg, or neither?

    Article • Hepatology, August 2008, Wiley

    Professor Amedeo LONARDO

  165. Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?

    Article • Internal and Emergency Medicine, July 2008, Springer Science + Business Media

    Professor Amedeo LONARDO, Stefano Ballestri

  166. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis

    Article • Clinical Science, July 2008, Portland Press Ltd.

    Professor Amedeo LONARDO

  167. Dysmetabolic changes associated with HCV: a distinct syndrome?

    Article • Internal and Emergency Medicine, February 2008, Springer Science + Business Media

    Professor Amedeo LONARDO

  168. The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology

    Article • Hepatology, December 2007, Wiley

    Professor Amedeo LONARDO, Stefano Ballestri

  169. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question

    Article • Nutrition Metabolism and Cardiovascular Diseases, November 2007, Elsevier

    Professor Amedeo LONARDO

  170. HCV and diabetes

    Article • Digestive and Liver Disease, August 2007, Elsevier

    Professor Amedeo LONARDO

  171. Is Cholangiocarcinoma Another Complication of Insulin Resistance: A Report of Three Cases

    Article • Metabolic Syndrome and Related Disorders, June 2007, Mary Ann Liebert Inc

    Professor Amedeo LONARDO, Stefano Ballestri

  172. Chicken or egg turned into head or belly

    Article • Journal of Hepatology, September 2006, Elsevier

    Professor Amedeo LONARDO

  173. ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis

    Article • Journal of Hepatology, June 2006, Elsevier

    Professor Amedeo LONARDO

  174. 17beta-estradiol prevents cytotoxicity from hydrophobic bile acids in HepG2 and WRL-68 cell cultures

    Article • Journal of Gastroenterology and Hepatology, May 2006, Wiley

    Professor Amedeo LONARDO

  175. Hepatitis C and steatosis: a reappraisal

    Article • Journal of Viral Hepatitis, February 2006, Wiley

    Professor Amedeo LONARDO

  176. Statins and HCV: A complex issue

    Article • Hepatology, January 2006, Wiley

    Professor Amedeo LONARDO

  177. Gender, fatty liver and GGT

    Article • Hepatology, January 2006, Wiley

    Professor Amedeo LONARDO

  178. Hepatic steatosis and insulin resistance: Does etiology make a difference?

    Article • Journal of Hepatology, January 2006, Elsevier

    Professor Amedeo LONARDO

  179. Fatty liver, carotid disease and gallstones: A study of age-related associations

    Article • World Journal of Gastroenterology, January 2006, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Professor Amedeo LONARDO

  180. Review article: hepatic steatosis and insulin resistance

    Article • Alimentary Pharmacology & Therapeutics, November 2005, Wiley

    Professor Amedeo LONARDO

  181. Review article: the metabolic syndrome and non-alcoholic fatty liver disease

    Article • Alimentary Pharmacology & Therapeutics, November 2005, Wiley

    Professor Amedeo LONARDO

  182. Gallstone disease in non-alcoholic fatty liver: Prevalence and associated factors

    Article • Journal of Gastroenterology and Hepatology, August 2005, Wiley

    Professor Amedeo LONARDO

  183. Pediatric gallstone disease in familial hypobetalipoproteinemia

    Article • Journal of Hepatology, July 2005, Elsevier

    Professor Amedeo LONARDO

  184. Should Nonalcoholic Fatty Liver Disease Be Renamed?

    Article • Digestive Diseases, January 2005, Karger Publishers

    Professor Amedeo LONARDO

  185. The wide spectrum of steatohepatitis

    Article • European Journal of Gastroenterology & Hepatology, October 2004, Wolters Kluwer Health

    Professor Amedeo LONARDO

  186. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease

    Article • Gastroenterology, February 2004, Elsevier

    Professor Amedeo LONARDO

  187. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver

    Article • Hepatology, January 2004, Wiley

    Professor Amedeo LONARDO

  188. Non-Organ-Specific Autoantibodies in Nonalcoholic Fatty Liver Disease: Prevalence and Correlates

    Article • Digestive Diseases and Sciences, November 2003, Springer Science + Business Media

    Professor Amedeo LONARDO

  189. Intestinal Wegener's granulomatosis in a patient with severe alpha-1-antitrypsin deficiency resulting from a unique combination of two deficiency alleles (PiZ and PiMProcida)

    Article • European Journal of Gastroenterology & Hepatology, December 2002, Wolters Kluwer Health

    Professor Amedeo LONARDO

  190. Apolipoprotein synthesis in nonalcoholic steatohepatitis

    Article • Hepatology, August 2002, Wiley

    Professor Amedeo LONARDO

  191. Growth hormone plasma levels in nonalcoholic fatty liver disease

    Article • The American Journal of Gastroenterology, April 2002, Springer Science + Business Media

    Professor Amedeo LONARDO

  192. Of liver, whisky and plants: a requiem for colchicine in alcoholic cirrhosis?

    Article • European Journal of Gastroenterology & Hepatology, April 2002, Wolters Kluwer Health

    Professor Amedeo LONARDO

  193. Growth hormone plasma levels in nonalcoholic fatty liver disease

    Article • The American Journal of Gastroenterology, April 2002, Wolters Kluwer Health

    Professor Amedeo LONARDO

  194. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study

    Article • Digestive and Liver Disease, March 2002, Elsevier

    Professor Amedeo LONARDO

  195. Is insulin resistance a pathogenic co-factor in hepatitis C virus-related disease and hepatocellular carcinoma?

    Article • Digestive and Liver Disease, February 2002, Elsevier

    Professor Amedeo LONARDO

  196. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5)

    Article • Journal of Hepatology, September 2000, Elsevier

    Professor Amedeo LONARDO

  197. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution

    Article • Journal of Gastroenterology and Hepatology, July 2000, Wiley

    Professor Amedeo LONARDO

  198. Fatty Liver and Nonalcoholic Steatohepatitis. Where Do We Stand and Where Are We Going?

    Article • Digestive Diseases, January 1999, Karger Publishers

    Professor Amedeo LONARDO

  199. Isolated jejunal Crohn's disease in a young adult presenting as fever of unknown origin

    Article • The American Journal of Gastroenterology, November 1998, Springer Science + Business Media

    Professor Amedeo LONARDO

  200. Article • Digestive Diseases and Sciences, January 1998, Springer Science + Business Media

    Professor Amedeo LONARDO

  201. Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B

    Article • Gastroenterology, October 1996, Elsevier

    Professor Amedeo LONARDO

  202. LETTER TO THE EDITOR

    Article • Journal of Gastroenterology and Hepatology, December 1994, Wiley

    Professor Amedeo LONARDO

  203. LETTER TO THE EDITOR

    Article • Journal of Gastroenterology and Hepatology, June 1994, Wiley

    Professor Amedeo LONARDO

  204. Are Routine Duodenal and Antral Biopsies Useful in the Management of “Functional” Dyspepsia?

    Article • Journal of Clinical Gastroenterology, September 1993, Wolters Kluwer Health

    Professor Amedeo LONARDO

  205. Right Colon Adenocarcinoma Presenting as Bacteroides fragilis Liver Abscesses

    Article • Journal of Clinical Gastroenterology, June 1992, Wolters Kluwer Health

    Professor Amedeo LONARDO

  206. Solitary Peutz-Jeghers Type Polyp of the Stomach

    Article • Endoscopy, May 1990, Thieme Publishing Group

    Professor Amedeo LONARDO

  207. Liver cirrhosis as A diabetogenic condition

    Article • Digestive Diseases and Sciences, January 1986, Springer Science + Business Media

    Dr Giampiero Francica, Professor Amedeo LONARDO

  208. Familial history in IBD

    Article • Digestive Diseases and Sciences, April 1985, Springer Science + Business Media

    Professor Amedeo LONARDO

  209. Lack of correlation between the laboratory findings and a series of steps in the clinical severity of chronic liver disease

    Article • La Ricerca in Clinica e in Laboratorio, October 1984, Springer Science + Business Media

    Professor Amedeo LONARDO